PT-141: the FDA-approved central melanocortin agonist for sexual desire

PT-141, also called bremelanotide and marketed as Vyleesi, is a synthetic cyclic heptapeptide that the FDA approved in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. it acts centrally on the MC4R melanocortin receptor and is mechanistically distinct from PDE5 inhibitors like sildenafil.

what is PT-141?

PT-141 is a synthetic cyclic heptapeptide with the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH, a lactam-bridged alpha-MSH analog optimized for selective agonism at the MC4R melanocortin receptor. it was developed by Palatin Technologies from the broader melanocortin agonist melanotan II.

PT-141 is built from the message core of alpha-melanocyte-stimulating hormone (alpha-MSH), truncated and cyclized into a rigid seven-residue ring around the His-D-Phe-Arg-Trp pharmacophore [1]. it differs from melanotan II by a single chemical edit at the C-terminus: melanotan II ends in an amide while PT-141 ends in a free hydroxyl. that change biases receptor preference toward MC4R and MC3R and away from MC1R, narrowing the pharmacology toward sexual behavior and meaningfully reducing tanning. the molecule was developed by Palatin Technologies after the field noticed an unexpected effect during early melanotan II tanning trials: men receiving the drug experienced spontaneous erections [2]. Palatin engineered PT-141 specifically to retain that sexual-behavior signal while reducing the off-target pigmentation effect.

commercially the drug is bremelanotide; in pre-approval literature and persistent community usage it is still PT-141. the US trade name is Vyleesi, originally marketed by AMAG Pharmaceuticals and now by Palatin directly. it is mechanistically related but not identical to its parent melanotan II and to the linear MC1R-selective afamelanotide (melanotan I).

how does it work?

PT-141 is a full agonist at MC4R, a Gs-coupled receptor expressed widely in the hypothalamus and limbic circuitry. activation raises cAMP, increases oxytocinergic and dopaminergic tone in regions involved in sexual reward and motivation, and amplifies the upstream desire and arousal signal that male and female sexual response circuits share.

the central mechanism is supported by multiple lines of evidence. MC4R-knockout mice show reduced sexual function and selective MC4R agonists restore it. erection responses in rats are blocked by central MC4R antagonists but not by peripheral injections, locating the site of action in the CNS [3]. in female rats, PT-141 increases appetitive sexual behaviors (solicitation, hops, darts) without changing reflex lordosis posture, a signature consistent with action on desire and motivation circuitry rather than reflex spinal pathways [4]. in human neuroimaging, MC4R agonism with bremelanotide enhanced activation in brain regions implicated in sexual processing (insula, anterior cingulate, orbitofrontal cortex) in response to erotic stimuli, providing direct evidence of central action in women with HSDD [5].

the central versus peripheral distinction is the single most important conceptual point in teaching PT-141. PDE5 inhibitors like sildenafil and tadalafil act peripherally on penile vascular smooth muscle and require sexual stimulation to produce an erection. PT-141 acts centrally to facilitate desire and arousal; the downstream effector is normal autonomic outflow rather than a peripheral vascular intervention. that is why PT-141 was hypothesized to work in PDE5-inadequate responders and in women, where peripheral vascular drugs have repeatedly failed.

what does the evidence show?

the strongest evidence is the two pre-specified Phase 3 RECONNECT trials, which enrolled 1,267 premenopausal women with acquired, generalized HSDD. bremelanotide produced statistically significant improvements over placebo on the co-primary endpoints (FSFI Desire and FSDS distress), but the effect size was modest and the placebo response was large.

Study 301 and Study 302 ran on identical pre-specified designs: 24 weeks double-blind followed by a 52-week open-label safety extension. in pooled analysis, mean change in FSFI-Desire was approximately +0.54 with bremelanotide versus +0.21 with placebo, and mean change in FSDS distress was approximately -0.74 versus -0.29 with placebo [6]. the long-term safety and efficacy extension confirmed durable effect with no new safety signals [7]. the satisfying-sexual-event count (a tertiary endpoint historically used as the HSDD benchmark) did not separate from placebo, raising interpretive debate about whether the desire and distress signal translates into the behavioral outcome that matters most to patients. discontinuation due to nausea was meaningfully higher than placebo at roughly 18 percent versus 2 percent.

outside the approved HSDD indication, the controlled evidence is much thinner. Phase 2 data in male erectile dysfunction (Diamond 2004, Rosen 2004) demonstrated dose-related erectile response and additive effect with sildenafil in PDE5-inadequate men [8], but the intranasal male ED program was halted in 2008 after the FDA flagged transient blood-pressure increases at higher doses. no Phase 3 male ED program has been completed, and the subcutaneous Vyleesi formulation has not been clinically developed for male ED.

FDA and regulatory status

the FDA approved bremelanotide as Vyleesi on June 21, 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. it is not approved for men, postmenopausal women, or any indication outside HSDD. WADA does not currently list bremelanotide as a prohibited substance.

the approved indication is narrow: not lifelong, not partner- or situation-specific, and not better explained by another medical condition, substance, or relational factor. the original developer Palatin licensed bremelanotide to AMAG Pharmaceuticals for commercialization; AMAG returned rights to Palatin in 2020. Vyleesi sits alongside flibanserin (Addyi), an oral daily 5-HT1A agonist approved for the same population in 2015. both products are HSDD-specific and have modest effect sizes; their existence reflects how difficult HSDD pharmacology has been historically. as a melanocortin agonist with no GH or anabolic profile, bremelanotide does not currently appear on the WADA prohibited list, though athletes should verify the current year's list before any competitive use.

safety profile and side effects

the dose-limiting adverse event is nausea, reported in roughly 40 percent of treated participants and the main reason for discontinuation. transient small blood pressure increases occur in a subset of users and contraindicate use in patients with uncontrolled hypertension or cardiovascular disease. focal hyperpigmentation (face, gingiva, breasts) occurs in a small minority and reflects residual MC1R activity.

the cardiovascular safety question shaped the entire development arc. an ambulatory blood pressure monitoring study (White 2017) characterized the transient BP rise as small in magnitude and short in duration after subcutaneous dosing, supporting subcutaneous use while explaining why the higher-dose intranasal program was discontinued [9]. the FDA label contraindicates bremelanotide in patients with uncontrolled hypertension and known cardiovascular disease, and recommends taking blood pressure before dosing. focal hyperpigmentation is the residual MC1R effect. the free-acid C-terminus of PT-141 reduces but does not abolish MC1R signaling; visible focal pigmentation occurred in roughly 1 percent of trial participants and was more common with more frequent dosing. nausea is mechanistically expected for any centrally-acting MC4R agonist, since MC4R is expressed in brainstem nausea circuits.

where it fits in peptide therapy

PT-141 sits in the melanocortin agonist family alongside its non-selective parent melanotan 2, the MC1R-selective afamelanotide (melanotan 1), and the MC4R-selective setmelanotide approved for rare monogenic obesity. the family relationship matters: all share the same minimal alpha-MSH message core but tune receptor preference and pharmacology in very different directions.

the closest structural relative is melanotan 2, which differs only in the C-terminal residue. melanotan 2 is a broad melanocortin agonist that produces tanning, appetite suppression, and sexual arousal; PT-141 is the desire-and-arousal-narrowed descendant. melanotan 2 has no FDA approval and is sold only in gray markets; PT-141 has full FDA approval in a narrow indication.

the MC1R-selective cousin is afamelanotide (melanotan 1), a linear NDP-MSH analog approved as SCENESSE for erythropoietic protoporphyria. it shares the alpha-MSH lineage but is engineered for the opposite end of the receptor profile, biased toward MC1R-mediated photoprotection rather than central sexual-behavior pathways. setmelanotide, an MC4R-selective cyclic agonist marketed as Imcivree, is approved for rare monogenic obesity syndromes including POMC, PCSK1, LEPR deficiency, and Bardet-Biedl syndrome. same primary receptor as PT-141, very different downstream emphasis (sustained appetite suppression rather than acute sexual-behavior facilitation), reflecting how MC4R biology splits into separable downstream programs. for broader context on how melanocortin agonists sit alongside other peptide classes, see our free peptides and your body module.